MGVS's two leading products, MultiGeneAngio and MultiGeneGraft have been approved by the FDA for clinical studies. Both products target large and growing patient populations with unmet needs.
cell therapy product for alleviating symptoms and signs of ischemia
in patients with peripheral arterial disease (PAD) and coronary
artery disease (CAD).
biosynthetic vascular graft lined with the patient’s own endothelial
cells, providing improved biocompatibility for patients undergoing
bypass surgery for PAD, as well as for renal disease patients who
need hemodialysis access site.